CNS Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for CNS Pharmaceuticals (CNSP).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$20Upside to Avg. PT+300.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 12, 2025	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$20
Mar 25, 2025	Maxim Group	Jason McCarthy	Downgrade	Buy→Hold	—
Sep 10, 2024	Maxim Group	Jason McCarthy	Upgrade	Hold→Buy	$300

Analyst Ratings News

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.

Benzinga Newsdesk

PRO
Maxim Group Downgrades CNS Pharma to Hold

Maxim Group analyst Jason McCarthy downgrades CNS Pharma (NASDAQ:CNSP) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $0.5 price target.

Benzinga Newsdesk

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Brookline Capital analyst Raja Kumaraguru initiates coverage on CNS Pharmaceuticals (NASDAQ:CNSP) with a Buy rating and announces Price Target of $10.

Benzinga Newsdesk

Benzinga's Top Upgrades, Downgrades For August 24, 2020

Upgrades

Benzinga Insights

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

Ladenburg Thalmann analyst Robert LeBoyer initiates coverage on CNS Pharmaceuticals (NASDAQ:CNSP) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

CNS Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

CNS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PRO
Maxim Group Downgrades CNS Pharma to Hold

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Benzinga's Top Upgrades, Downgrades For August 24, 2020

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

CNS Pharmaceuticals Inc

뉴스

파트너 / 기고자

벤징가 글로벌

CNS Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PROMaxim Group Downgrades CNS Pharma to Hold

PROMaxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PROBrookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

Benzinga's Top Upgrades, Downgrades For August 24, 2020

PROLadenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11

People Also Watch

People Also Watch

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $20 Price Target

PRO
Maxim Group Downgrades CNS Pharma to Hold

PRO
Maxim Group Upgrades CNS Pharma to Buy, Announces $0.5 Price Target

PRO
Brookline Capital Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $10

PRO
Ladenburg Thalmann Initiates Coverage On CNS Pharmaceuticals with Buy Rating, Announces Price Target of $11